Merck Engages in Talks to Acquire Revolution Medicines in Potential $32 Billion Deal

Merck & Co. is reportedly in discussions to acquire cancer drug developer Revolution Medicines, with the deal valued between $28 billion and $32 billion.

 

According to recent reports, the negotiations are ongoing, and a final agreement may take several weeks to materialize.

 

Other major pharmaceutical companies are also expressing interest in Revolution Medicines, indicating a competitive acquisition landscape.

 

Revolution Medicines specializes in developing therapies targeting RAS proteins, which are implicated in various cancers.

 

The company's lead candidate, daraxonrasib, is an investigational oral RAS(ON) multi-selective inhibitor designed to address multiple RAS mutations.

 

Merck's pursuit of Revolution Medicines aligns with its strategy to diversify its oncology portfolio, especially as its blockbuster immunotherapy, Keytruda, faces patent expirations in the coming years.

 

In recent years, Merck has actively expanded its pipeline through acquisitions, including the purchase of Verona Pharma for approximately $10 billion, adding the COPD treatment Ohtuvayre to its portfolio.

 

As of January 10, 2026, Merck's stock price stood at $110.53, reflecting a slight decrease of 0.00432% from the previous close.

 

Revolution Medicines' stock experienced a significant increase, reaching $118.64, up 10.69% amid acquisition speculations.

 

While the potential acquisition could significantly enhance Merck's oncology offerings, the competitive nature of the bidding process and the substantial valuation underscore the complexities involved in finalizing such a deal.

 

Industry observers will be closely monitoring developments as Merck navigates this strategic move to strengthen its position in the oncology market.